Recreational ecstasy use and the neurotoxic potential of MDMA: current status of the controversy and methodological issues

References

• et al. National Drug Strategy Household Survey. Australian Institute of Health and Welfare, Department of Health and Aged Care, Canberra 2001
   Google Scholar
• Ecstasy: the complete guide., J Holland. Park Street Press, Rochester, VT 2001
   Google Scholar
• Check E. The ups and downs of ecstasy. Nature 2004; 429: 126–128
   PubMed Web of Science ®Google Scholar
• Cole J C, Sumnall H R. Altered states: the clinical effects of ecstasy. Pharmacol Ther 2003; 98: 35–58
   PubMed Web of Science ®Google Scholar
• Battaglia G, Sharkey J, Kuhar M J, de Souza E B. Neuroanatomic specificity and time course of alterations in rat brain serotonergic pathways induced by MDMA (3,4-methylene-dioxymethamphetamine): assessment using quantitative autoradiography. Synapse 1991; 8: 249–260
   PubMedGoogle Scholar
• Callahan B T, Cord B J, Ricaurte G A. Long-term impairment of anterograde axonal transport along fiber projections originating in the rostral raphe nuclei after treatment with fenfluramine or MDMA. Synapse 2001; 40: 113–121
   PubMed Web of Science ®Google Scholar
• Ricaurte G A, DeLanney L E, Irwin I, Langston J W. Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administration. Brain Res 1988; 446: 165–168
   PubMed Web of Science ®Google Scholar
• Sabol K E, Lew R, Richards J B, Vosmer G L, Seiden L S. Methylenedioxy-methamphetamine-induced serotonin deficits are followed by partial recovery over a 52-week period. Part I: Synaptosomal uptake and tissue concentrations. J Pharmacol Exp Ther 1996; 276: 846–854
   PubMedGoogle Scholar
• Hatzidimitriou G, McCann U D, Ricaurte G A. Altered serotonin innervation patterns in the forebrain of monkeys treated with (+/−) 3,4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery. J Neurosci 1999; 19: 5096–5107
   PubMed Web of Science ®Google Scholar
• Parrott A C. Human psychopharmacology of ecstasy (MDMA): a review of 15 years of empirical research. Hum Psychopharmacol Clin Exp 2001; 16: 557–577
   PubMed Web of Science ®Google Scholar
• Liechti M E, Vollenweider F X. Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies. Hum Psychopharmacol Clin Exp 2001; 16: 589–598
   PubMed Web of Science ®Google Scholar
• Gowing L R, Henry-Edwards S M, Irvine R J, Ali R L. The health effects of ecstasy: A literature review. Drug Alcohol Rev 2002; 21: 53–63
   PubMed Web of Science ®Google Scholar
• Back-Madruga C, Boone K B, Chang L, et al. Neuropsychological effects of 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) in recreational users. Clin Neuropsychol 2003; 17: 446–459
   PubMed Web of Science ®Google Scholar
• Bhattachary S, Powell J H. Recreational use of MDMA or ‘ecstasy’: evidence for cognitive impairment. Psychol Med 2001; 31: 647–658
   PubMed Web of Science ®Google Scholar
• Bolla K I, McCann U, Ricaurte G A. Memory impairment in abstinent MDMA (‘ecstasy’) users. Neurology 1998; 51: 1532–1537
   PubMed Web of Science ®Google Scholar
• Fox H C, Parrott A C, Turner J JD. Ecstasy use: cognitive deficits related to dosage rather than to self-reported problematic use of the drug. J Psychopharmacol 2001; 15: 273–281
   PubMed Web of Science ®Google Scholar
• Fox H C, Toplis J JD, Parrott A C. Auditory verbal learning in drug-free polydrug users. Hum Psychopharmacol Clin Exp 2001; 16: 613–618
   PubMed Web of Science ®Google Scholar
• Fox H C, McLean A, Turner J J, Parrott A C, Rogers R, Sahakian B J. Neuropsychological evidence of a relatively selective profile of temporal dysfunction in drug-free MDMA (‘ecstasy’) polydrug users. Psychopharmacology 2002; 162: 203–214
   PubMed Web of Science ®Google Scholar
• Gouzoulis-Mayfrank E, Thimm B, Rezk M, Hensen G, Daumann J. Memory impairment suggests hippocampal dysfunction in abstinent ecstasy users. Prog Neuro-Psychopharmacol Biol Psychiatry 2003; 27: 819–827
   PubMedGoogle Scholar
• Hanson K L, Luciana M. Neurocognitive function in users of MDMA: the importance of clinically significant patterns of use. Psychol Med 2004; 34: 229–246
   PubMed Web of Science ®Google Scholar
• McCann U D, Merti M, Eligulashvii V, Ricaurte G A. Cognitive performance in (+/−) 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) users: a controlled study. Psychopharmacology 1999; 143: 417–425
   PubMed Web of Science ®Google Scholar
• Morgan M J. Memory deficits associated with recreational use of ecstasy (MDMA. Psychopharmacology 1999; 141: 30–36
   PubMed Web of Science ®Google Scholar
• Morgan M J, McFie L, Fleetwood L H, Robinson J A. Ecstasy (MDMA): are the psychological problems associated with its use reversed by prolonged abstinence?. Psychopharmacology 2002; 159: 294–303
   PubMed Web of Science ®Google Scholar
• Parrott A C, Lees A, Garnham N J, Jones M, Wesnes K. Cognitive performance in recreational users of MDMA or ‘ecstasy’: evidence for memory deficits. J Psychopharmacol 1998; 12: 79–83
   PubMed Web of Science ®Google Scholar
• Reneman L. Memory disturbances in ‘Ecstasy’ users are correlated with altered brain serotonin neurotransmission. Psychopharmacology 2000; 148: 322–324
   PubMed Web of Science ®Google Scholar
• Reneman L, Booji J, de Bruin K, et al. Effects of dose, sex and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons. Lancet 2001; 358: 1864–1869
   PubMed Web of Science ®Google Scholar
• Heffernan T M, Jarvis H, Rodgers J, Scholey A B, Ling J. Prospective memory, everyday cognitive failure and central executive function in recreational users of Ecstasy. Hum Psychopharmacol Clin Exp 2001; 16: 607–612
   PubMed Web of Science ®Google Scholar
• Rodgers J, Buchanan T, Scholey A, Heffernan T, Ling J, Parrott A. Differential effects of Ecstasy and cannabis on self-reports of memory ability: a web-based study. Hum Psychopharmacol Clin Exp 2001; 16: 619–625
   PubMed Web of Science ®Google Scholar
• Zakzanis K K, Young D A, Campbell Z. Prospective memory impairment in abstinent MDMA (‘ecstasy’) users. Cogn Neuropsychiatr 2003; 8: 141–153
   PubMedGoogle Scholar
• Halpern J H, Pope H G, Sherwood A R, Barry S, Hudson J I, Yurgelun-Todd D. Residual neuropsychological effects of illicit 3,4-methelenedioxymethamphetamine (MDMA) in individuals with minimal exposure to other drugs. Drug Alcohol Depend 2004; 75: 149–152
   PubMedGoogle Scholar
• Thomasius R, Petersen K, Buchert R, et al. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users. Psychopharmacology 2003; 167: 85–96
   PubMed Web of Science ®Google Scholar
• Wareing M, Fisk J E, Murphy P N. Working memory deficits in current and previous users of MDMA (‘ecstasy’). Br J Psychol 2000; 91: 181–188
   PubMed Web of Science ®Google Scholar
• Zakanis K K, Young D A. Executive function in abstinent MDMA (‘ecstasy’) users. Med Sci Monitor 2001; 7: 1292–1298
   PubMedGoogle Scholar
• Moeller F G, Dougherty D M, Steinberg J L, et al. Heavy ‘ecstasy’ use is associated with increased impulsivity. Addict Disord 2002; 1: 47–52
   Google Scholar
• Obrocki J, Schmoldt A, Buchert R, Andresen B, Petersen K, Thomasius R. Specific neurotoxicity of chronic use of ecstasy. Toxicol Lett 2002; 127: 285–297
   PubMedGoogle Scholar
• McCann U D, Szabo Z, Scheffel U, Dannals R F, Ricaurte G A. Positron emission tomography evidence of toxic effect of MDMA (‘ecstasy’) on brain serotonin neurons in human beings. Lancet 1998; 352: 1433–1437
   PubMed Web of Science ®Google Scholar
• Reneman L, Majoie C B, Flick H, den Heeten G J. Reduced N-acetylaspartate levels in the frontal cortex of MDMA (Ecstasy) users: preliminary results. Am J Neuroradiol 2002; 23: 231–237
   PubMedGoogle Scholar
• Gouzoulis-Mayfrank E, Daumann J, Sass H. Long-term neurotoxic brain damage in ecstasy (MDMA) users. A review of the literature. Nervenarzt 2002; 73: 405–421
   Google Scholar
• Buchert R, Thomasius R, Nebeling B, et al. Long-term effects of ‘Ecstasy’ use on serotonin transporters of the brain investigated by PET. J Nucl Med 2003; 44: 375–384
   PubMed Web of Science ®Google Scholar
• Grob C. Deconstructing ecstasy: the politics of MDMA research. Addict Res 2000; 8: 549–588
   Web of Science ®Google Scholar
• Kish S J. How strong is the evidence that brain serotonin neurons are damaged in human users of ecstasy?. Pharmacol Biochem Behav 2002; 71: 845–855
   PubMed Web of Science ®Google Scholar
• Taffe M A, Weed M R, Davis S, et al. Functional consequences of repeated MDMA treatment in rhesus monkeys. Neuropsychopharmacology 2002; 24: 230–239
   Google Scholar
• Winsauer P J, McCann U D, Yuan J, et al. Effects of fenfluramine, m-CPP and triazolam on repeat-acquisition in squirrel monkeys before and after neurotoxic MDMA administration. Psychopharmacology (Berl) 2002; 159: 388–396
   PubMedGoogle Scholar
• Bowyer J F, Young J F, Slikker W, et al. Plasma levels of parent compound and metabolites after doses of either d-fenfluramine or d-3,4-methylenedioxymethamphetamine (MDMA) that produces long-term serotonergic alterations. Neurotoxicology 2003; 24: 379–390
   PubMedGoogle Scholar
• Gouzoulis-Mayfrank E, Becker S, Pelz S, Tuchtenhagen F, Daumann J. Neuroendocrine abnormalities in recreational ecstasy (MDMA) users: is it ecstasy or cannabis?. Biol Psychiatry 2002; 51: 766–769
   PubMedGoogle Scholar
• Bolla K I, Brown K, Eldreth D, Tate K, Cadet J L. Dose-related neurocognitive effects of marijuana use. Neurology 2002; 59: 1337–1343
   PubMed Web of Science ®Google Scholar
• Pope H G, Gruber A J, Hudson J I, Huestis M A, Yurgelun-Todd D. Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry 2001; 58: 909–915
   PubMed Web of Science ®Google Scholar
• Barker B, Lyvers M. Neuropsychological performance in human ecstasy users: A test of the ecstasy-induced serotonin neurotoxicity hypothesis. Presented at the Annual Convention of the Australian Psychological Society. Gold CoastAustralia September, 2002
   Google Scholar
• Croft R J, Mackay A J, Mills A TD, Gruzelier J GH. The relative contribution of ecstasy and cannabis to cognitive impairment. Psychopharmacology 2001; 153: 373–379
   PubMed Web of Science ®Google Scholar
• Dafters R I, Hoshi R, Talbot A C. Contribution of cannabis and MDMA (‘ecstasy’) to cognitive changes in long-term polydrug users. Psychopharmacology (Berl 2004; 17: 405–410
   Google Scholar
• Daumann J, Pelz S, Becker S, Tuchtenhagen F, Gouzoulis-Mayfrank E. Psychological profile of abstinent recreational Ecstasy (MDMA) users and significance of concomitant cannabis use. Hum Psychopharmacol Clin Exp 2001; 16: 627–633
   PubMed Web of Science ®Google Scholar
• Simon N G, Mattick R P. The impact of regular ecstasy use on memory function. Addiction 2002; 97: 1523–1529
   PubMed Web of Science ®Google Scholar
• Lyvers M, Barker B, Bradnam J. Memory, cognition, mood and impulsivity in current and former users of MDMA (ecstasy): testing the serotonergic neurotoxicity hypothesis. J Psychosom Res 2003; 55: 156–157
   Google Scholar
• Gurtman C G, Morley K C, Li K M, Hunt G E, McGregor I S. Increased anxiety in rats after MDMA: Association with serotonin depletion. Eur J Pharmacol 2002; 446: 89–96
   PubMedGoogle Scholar
• Hollander E, DeCaria C M, Nitescu A, et al. Serotonergic function in obsessive – compulsive disorder. Arch Gen Psychiatry 1992; 49: 21–28
   PubMed Web of Science ®Google Scholar
• Zakzanis K K, Young D A. Memory impairment in abstinent MDMA (‘ecstasy’) users: a longitudinal investigation. Neurology 2001; 56: 966–969
   PubMed Web of Science ®Google Scholar
• Verbaten M N. Specific memory deficits in ecstasy users? The results of a meta-analysis. Hum Psychopharmacol Clin Exp 2003; 18: 281–290
   PubMedGoogle Scholar
• Cloninger C R. Neurogenetic adaptive mechanisms in alcoholism. Science 1987; 23: 410–415
   Google Scholar
• Conrod P J, Peterson J B, Pihl R O. Disinhibited personality and sensitivity to alcohol reinforcement: independent correlates of drinking behavior in sons of alcoholics. Alcohol Clin Exp Res 1997; 21: 1320–1332
   PubMedGoogle Scholar
• Giancola P R, Martin C S, Tarter R E, Pelham W E, Moss H B. Executive cognitive functioning and aggressive behavior in preadolescent boys at high risk for substance abuse/dependence. J Stud Alcohol 1996; 57: 352–359
   PubMed Web of Science ®Google Scholar
• Higley J D, Linnoila M. A nonhuman primate model of excessive alcohol intake: personality and neurobiological parallels of Type I- and Type II-like alcoholism. Recent developments in alcoholism, vol. 13. Alcohol and violence, M Galanter. Plenum Press, New York 1997; 191–219
   Google Scholar
• LeMarquand D G, Pihl R O, Young S N, et al. Tryptophan depletion, executive functions, and disinhibition in aggressive, adolescent males. Neuropsychopharmacology 1998; 19: 333–341
   PubMed Web of Science ®Google Scholar
• Lyvers M. ‘Loss of control’ in alcoholism and drug addiction: a neuroscientific interpretation. Exp Clin Psychopharmacol 2000; 8: 225–249
   PubMed Web of Science ®Google Scholar
• Nielsen D A, Virkkunen M, Lappalainen J, et al. A tryptophan hydroxylase gene marker for suicidality and alcoholism. Arch Gen Psychiatry 1998; 55: 593–602
   PubMed Web of Science ®Google Scholar
• Pihl R O, Peterson J B. Alcoholism: the role of different motivational systems. J Psychiatr Neurosci 1995; 20: 372–396
   PubMed Web of Science ®Google Scholar
• Tarter R E, Moss H B, Vanyukov M M. Behavioral genetics and the etiology of alcoholism. The genetics of alcoholism, H Begleiter, B Kissin. Oxford University Press, New York 1995; 294–326
   Google Scholar
• Virkkunen M, Linnoila M. Serotonin in early-onset alcoholism. Recent developments in alcoholism, vol. 13. Alcohol and violence, M Galanter. Plenum Press, New York 1997; 173–189
   Google Scholar
• Croft R J, Klugman A, Baldeweg T, Gruzelier J H. Electrophysiological evidence of serotonergic impairment in long-term MDMA (‘ecstasy’) users. Am J Psychiatry 2001; 158: 1687–1692
   PubMed Web of Science ®Google Scholar
• Pope H G, Gruber A J, Hudson J I, Cohane G, Heustis M A, Yurgelun-Todd D. Early-onset cannabis use and cognitive deficits: what is the nature of the association?. Drug Alcohol Depend 2003; 69: 303–310
   PubMed Web of Science ®Google Scholar
• Curran H V. Is MDMA (‘Ecstasy’) neurotoxic in humans? An overview of evidence and methodological problems in research. Neuropsychobiology 2000; 42: 34–41
   PubMed Web of Science ®Google Scholar
• Hurley R A, Reneman L, Taber K H. Ecstasy in the brain: a model for neuroimaging. J Neuropsychiatr Clin Neurosci 2002; 14: 125–129
   PubMedGoogle Scholar
• Ricaurte G A, Yuan J, Hatzidimitriou G, Cord B J, McCann U D. Retraction: severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA (‘ecstasy’). Science 2003; 301: 1479
   PubMedGoogle Scholar
• Olney J W, Labruyere J, Wang G, Wozniak D F, Price M T, Sesma M A. NMDA antagonist neurotoxicity: mechanism and prevention. Science 1991; 254: 1515–1518
   PubMed Web of Science ®Google Scholar
• Cole J C, Bailey M, Sumnall H R, Wagstaff G F, King L A. The content of ecstasy tablets: implications for the study of their long-term effects. Addiction 2002; 97: 1531–1536
   PubMed Web of Science ®Google Scholar
• Irvine R, Keane M, Felgate P, Callaghan P, White J. Blood drug concentrations and clinical status of dance party participants. Presented at the Annual Meeting of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists. SydneyAustralia December, 2003
   Google Scholar
• Parrott A C. Is ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, their dosage levels, and the changing perceptions of purity. Psychopharmacology (Berl 2004; 173: 234–241
   PubMed Web of Science ®Google Scholar
• Mann J J, Huang Y Y, Underwood M D, et al. A serotonin transporter gene promoter polymorphism (5-HTTLPR) and prefrontal cortical binding in major depression and suicide. Arch Gen Psychiatry 2000; 57: 729–738
   PubMed Web of Science ®Google Scholar
• Liechti M, Gamma A, Vollenweider F. Gender differences in the subjective effects of MDMA. Psychopharmacology 2001; 154: 161–168
   PubMed Web of Science ®Google Scholar
• Aghajanian G K, Lieberman J A. Response. Neuropsychopharmacology 2001; 24: 335–336
   Google Scholar
• Ricaurte G A, Yuan J, Hatzidimitriou G, Cord B J, McCann U D. Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA (‘ecstasy’). Science 2002; 297: 2260–2263
   PubMed Web of Science ®Google Scholar
• Kish S J, Furukawa Y, Ang L, Vorce B S, Kalasinsky K S. Striatal serotonin is depleted in brain of a human MDMA (ecstasy) user. Neurology 2000; 55: 294–296
   PubMedGoogle Scholar
• Kish S J. What is the evidence that ecstasy (MDMA) can cause Parkinson's disease?. Movement Dis 2003; 18: 1219–1223
   PubMedGoogle Scholar
• Nature Editorial. Ecstasy's after effects: following the retraction of a high-profile paper, the US research agency that supports research on drug abuse needs to ensure its independence from intense political pressure to prove that recreational drugs are harmful. Nature 2003; 425: 223
   Google Scholar
• Vollenweider F X, Jones R T, Baggott M J. Caveat emptor: editors beware. Neuropsychopharmacology 2001; 24: 461–463
   PubMed Web of Science ®Google Scholar
• Ludewig S, Ludewig K, Hasler F, Vollenweider F X. No lasting effects of moderate doses of MDMA (Ecstasy) on memory performance and mood states in healthy humans. Biol Psychiatry 2003; 53(Suppl)205S
   Google Scholar